See why LUMIGAN® 0.01% may be right for lowering the high eye pressure of your open-angle glaucoma or ocular hypertension

Lumigan Logo

There is no FDA-approved generic of LUMIGAN® 0.01%.

There is no FDA-approved generic of LUMIGAN® 0.01%.

Eligible commercially-insured patients may pay as little as

$30* per 90-day prescription fill

That's as little as $10 a month for a 90-day supply

You can also enroll for discounts by





You can also enroll for discounts by



Or Texting


*Maximum savings limits apply; patient out-of-pocket expense will vary depending on insurance coverage. Offer valid for patients with commercial prescription insurance coverage and a valid prescription for LUMIGAN® 0.01%, COMBIGAN®, or ALPHAGAN® P 0.1%. Offer not valid for patients enrolled in Medicare, Medicaid, or any other federal, state, or government-funded healthcare program. See At Your Service Savings Program Terms, Conditions, and Eligibility Criteria at SaveWithAYS.com.

AYS Alerts: Msg and data rates apply. Msg frequency depends on user. Reply HELP for help; reply STOP to cancel. Consent to texts not required to sign up for offer. View our Mobile Terms & Conditions and Privacy Policy.


LUMIGAN® (bimatoprost ophthalmic solution) 0.01% is used for the reduction of high eye pressure, also called intraocular pressure (IOP), in people with open-angle glaucoma or ocular hypertension.


Do not use LUMIGAN® 0.01% if you are allergic to any of the ingredients.

LUMIGAN® 0.01% can cause increased brown coloring of the iris, which may be permanent. LUMIGAN® 0.01% can cause darkening of the eyelid skin and eyelashes, which may be reversible after treatment is stopped. The long-term effects of the increased dark coloring are not known.

LUMIGAN® 0.01% may slowly increase the growth and thickness of eyelashes, which is usually reversible after treatment is stopped.

Prostaglandin analogs, including bimatoprost (the active ingredient in LUMIGAN® 0.01%), have been reported to cause inflammation inside the eye and may make existing inflammation inside the eye worse.

Macular edema (swelling of the macula, the central part of the retina), including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution. Use caution if you use LUMIGAN® 0.01% and you don’t have your natural lens, have a torn posterior lens capsule and an artificial lens implant, or have a known risk factor for macular edema.

Avoid allowing the tip of the dispensing bottle to touch the eye, anything around the eye, fingers, or any other surface to avoid contamination by common bacteria known to cause eye infections (bacterial keratitis). Using contaminated solutions can cause serious damage to the eye and loss of vision.

If you have eye surgery, eye trauma, or infection, or develop any eye reactions, immediately consult with your physician about continuing the use of LUMIGAN® 0.01%.

LUMIGAN® 0.01% contains an ingredient that may be absorbed by and cause discoloration of soft contact lenses. If you wear contact lenses, remove them before using LUMIGAN® 0.01%. Then wait 15 minutes after using LUMIGAN® 0.01% before you put your contacts back into your eyes.

If you use more than one drug in the eye, be sure to wait at least 5 minutes between each drug application.

The most common side effect in the clinical trial was eye redness. Other side effects include eye irritation, eye pain, itchy eyes, discoloration of skin/eyelids, and blurred vision. These are not all of the possible side effects with LUMIGAN® 0.01%. Tell your doctor if you have any side effect that bothers you or that does not go away.

Please see full Prescribing Information for LUMIGAN® at https://www.rxabbvie.com/pdf/lumigan_pi.pdf.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.